The Opinion article from Gabriel Ichim and Stephen W. G. Tait, ' A fate worse than death: apoptosis as an oncogenic process' (Nat. Rev. Cancer 16, 539-548; 2016) 1 , highlights intrinsic mechanisms of failure of com monly used cancer therapies that are heav ily dependent on apoptosis. Homeostatic mechanisms are triggered by the presence of dying cells within tissues, favouring the sur vival of residual tumoural cells in the tumour micro environment 2 . Understanding these homeostatic mechanisms will provide action able targets to enhance the effectiveness of therapeutic strategies used in the clinic.
The presence of apoptotic cells with sub tumorigenic numbers of mouse melanoma cells promoted tumour engraftment and growth, in a mechanism dependent on the recruitment of inflammatory cells 3 . In a separate study, it was shown that clearance of dying cells by tumour macrophages shifts them towards the pro tumorigenic M2 phenotype by mechanisms involving the receptor for the lipid mediator plateletactivating factor (PAF), a member of the 1alkyl,2acylglycerophosphocholine subclass of lipids 4 . Lipid mediators are generated in the tumour microenvironment and can modu late tumour growth. Prostaglandin E 2 (PGE 2 ) is among the most studied molecular effec tors of tumour repopulation following chemo therapy 5 . PGE 2 is derived from the metabolism of membrane phospho lipids, through the action of phospholipase A 2 (PLA 2 ). Both Ca 2+ dependent PLA 2 (cPLA 2 ) and Ca 2+ independent PLA 2 (iPLA 2 ; also known as PLA2G6) 6 cleave phosphatidyl choline into arachidonic acid and lyso phosphatidylcholine (FIG. 1) . Although arachidonic acid can be enzymatically con verted into prostanoids, including PGE 2 , lysophosphatidylcholine is converted into PAF through the action of lysophosphatidyl choline acyltransferases (LPCAT1, LPCAT2, LPCAT3 and LPCAT4) 7 . Therefore, in situ ations in which PGE 2 is produced, depend ing on the levels of LPCAT expression, PAF is also produced. In a positive feedback loop, through the activation of its receptor (PAFR), PAF induces either activation of PLA 2 (REF. 8) or induction of cyclooxygenase 2 (COX2) expression 9, 10 , leading to the further release of PGE 2 . The contribution of PAFRdependent signalling in tumour repopulation was also demonstrated in its response to chemo therapy and radiotherapy. PAF protects tumour cells from druginduced cell death, and the admin istration of PAFR antagonists blocks its protective effect [11] [12] [13] . Radiation therapy is among the most potent inducers of PAFR ligands through the oxidation of phospholipids 14 , whose forma tion is independent of LPCAT. Regardless of their origin, however, PAFR ligands favour PGE 2 production. Experimental radia tion therapy was more effective in tumour engrafted PAFRknockout mice, as compared with wild type, owing to decreased tumour repopulation in animals devoid of PAFR signalling. Moreover, PAFR ligands induce tissue remodelling and angiogenic cytokine production, through macrophage polariza tion towards the M2 phenotype. The accu mulating evidence for the involvement of PAFRdependent signalling in the survival response of tumours to chemo and radio therapy supports the concept that PAFR antagonists could be used for adjuvant can cer therapy. Several antagonists have been
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Roger Chammas, Luciana Nogueira de Sousa Andrade and Sonia Jancar Figure 1 | Pro-oncogenic effects of platelet-activating factor (PAF) and PAF-like molecules after a cell death stimulus. In response to a death stimulus, activated caspase-3 (CASP3) promotes activation of phospholipase A 2 (PLA 2 ) , which cleaves membrane phospholipids such as phosphatidylcholine (PC), releasing arachidonic acid, which can be converted into prostaglandin E 2 (PGE 2 ) and lysophosphatidylcholine (LPC or lyso-PAF (LPAF)), which can then be converted into PAF through the activity of lysophosphatidylcholine acyltransferase (LPCAT). PAF acts in a positive autocrine loop to further activate PLA 2. PAF also interacts with intracellular PAF receptor (PAFR), activating nuclear factor-κB (NF-κB), which in turn induces cyclooxygenase 2 (COX2) transcription, thus potentiating PGE 2 production. Both PAF and PGE 2 act as pro-survival stimuli in tumour cells, promoting proliferation of the surviving cells and leading to tumour repopulation. Activation of PAFR in macrophages promotes reprogramming towards an anti-inflammatory and pro-tumorigenic profile (M2 genes). Moreover, irradiation and chemotherapy generate a wide range of PAFR ligands (PAF-like) in the tumour microenvironment that act as PAFR agonists (dashed arrows), amplifying the effect of PAFR activation in tumour cells and macrophages.
developed in the past, but none has yet been tested for clinical use in cancer. PAFR antag onists are likely to complement strategies that target tumourassociated macrophages (colonystimulating factor 1 receptor (CSF1R) antagonists) and PGE 2 (COX2 inhibitors), which, together, will improve the efficacy of apoptogenic therapies.
